Nektar Therapeutics presented data at the American Association for Cancer Research (AACR) 100th Annual Meeting demonstrating that NKTR-105, a novel PEGylated form of docetaxel, has superior anti-tumour activity, as well as greater and sustained exposure in plasma and tumour tissue, over docetaxel in preclinical models.
The details can be read here.
No comments:
Post a Comment